Welcome to the Treat-MS study website


This part of the site is intended for site coordinators and investigators. We will be posting information about the study here: enrollment updates, tips on completing the study forms, best practices, etc.

Please be sure to subscribe so that you will receive notices of new postings.

  28 Hits
28 Hits

Setting up the VICTAS Trial

Welcome, VICTAS Sites!

The project team is hard at work setting up the VICTAS trial. We are currently developing the electronic case forms, identifying sites, developing training materials, and doing all the other many tasks that will be needed to undertake this clinical trial. We'll post more information here soon so be sure to subscribe to this blog to receive update notices.

The graphic below shows some of the activities we need to complete before we GO LIVE.


Continue reading
  3637 Hits
3637 Hits

MISTIE 3 in the final stretch!

The MISTIE III clinical trial, evaluating catheter-delivered thrombolysis for the treatment of intracerebral hemorrhage, is on track to complete enrollment in mid-2017.  The 400th patient, out of 500 planned, was enrolled on 01-November!

Currently, there are 62 active sites which have screened over 15,000 subjects. There were 173 patients enrolled over the trailing twelve months, for an average of 14.4 patients randomized each month, albeit there is notable month-to-month variability with enrollment generally being higher in the winter months. Extrapolating, that suggests that enrollment should complete by June, which would be two months ahead of plan. Follow-up of the last enrolling patient should be complete 12 months later.

  2980 Hits
2980 Hits

MISTIE III Enrollment Review for July 2016


As of end-July 2016, we are at 356 enrollments (of 500). Over the trailing 12-month period (TTM), we have enrolled 178 subjects, an average of 14.8 per month. The number of actively-recruiting sites each month (activated less closures and temporary holds) is relatively stable at around 75 sites, and it seems likely that the current average enrollment rate will continue. Extrapolating, we are therefore on track to complete enrollment in around 10 months (May-2017), about 2 months ahead of plan. In our enrollment data, there is notable month-to-month variability, a possible seasonality effect, and a limited performance history with the later-starting ex-US sites that suggest a 2-month collar is reasonable (e.g., enrollment should complete in Mar-Jul period).



Enrollment at the Australia-Asia sites, managed by the George Institute (GI or TGI), is averaging around 0.75 randomizations per month (over the TTM period). At this rate, they will contribute around 20 to 24 subjects by enrollment completion.

Enrollment in the MTI substudy (across 23 of the M3 sites) is proceeding smoothly at approximately 4.3 subjects per month.  At completion of enrollment in the overall trial, there should be approximately 90 subjects in this substudy (red line in the graph below).



96 Normal 0 false false false false EN-US X-NONE X-NONE


  2945 Hits
2945 Hits

Welcome to the EDGE Newton-2 Study!

Edge Therapeutics Logo

The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical trial Newton-2 (Protocol #EG-01-1962-03) evaluating a new treatment for certain patients with aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that the blinded assessors at the clinical sites are well versed on the neurologic outcome assessments in this trial. Because the outcome on the GOSE rating scale is the primary endpoint in this study, it is imperative that the assessor has a thorough understanding of the survey methodology, including the ability to perform a thorough assessment of the extent of disability at baseline, prior to the aSAH. We are providing this online training course, assessment tools, and informational updates. Please see the menu for these materials.

Additionally, please feel free to contact us with any questions you may have. Meanwhile, we look forward to working with you!


  6608 Hits
6608 Hits

MISTIE-3 Site Locations